News & Events
News & Events
Institut Pasteur Korea Signs MOU with GEMCRO to Collaborate on Preclinical Research Using Genetically Engineered Mice (GEM)
2025-09-17
Institut Pasteur Korea Signs MOU with GEMCRO to Collaborate on Preclinical Research Using Genetically Engineered Mice (GEM)
- Strengthening infectious disease research through humanized mouse platforms -
- Strengthening infectious disease research through humanized mouse platforms -
.png)
(Sep. 17, 2025, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) announced on September 17 that it signed a memorandum of understanding (MOU) with GEMCRO on September 5 to collaborate on infectious disease research and therapeutic development using genetically engineered mice (GEM), including humanized models.
The agreement outlines plans to investigate the pathogenesis of infectious diseases using GEM-based disease models, co-develop and validate novel therapeutic candidates in preclinical studies, share access to research facilities and resources, and foster the training and exchange of next-generation research professionals.
By combining IPK’s infectious disease research infrastructure—including its vaccine and therapeutic development platforms—with GEMCRO’s advanced gene-edited GEM platforms, the two organizations aim to establish a more precise and reliable preclinical validation system. This partnership is expected to accelerate the development of innovative therapeutics at a global level while strengthening the competitiveness of Korea’s biohealth industry.
IPK is a leading infectious disease research institute conducting both fundamental and translational research to accelerate the development of vaccines and therapeutics. It has achieved notable milestones, including the development of new treatments for drug-resistant tuberculosis, and actively supports collaborative research through its open-lab infrastructure such as the Virus Research Resource Center (RRC).
GEMCRO is a biotechnology company specializing in the development of genetically engineered mice (GEM) using CRISPR/Cas9 technology. The company has created various humanized GEM models tailored for infectious disease research, including the hiACE2 model for COVID-19, and provides immunodeficient N2G mouse strains essential for humanization. These platforms enable GEMCRO to offer customized preclinical research solutions to researchers both in Korea and abroad.
Sung Key Jang, CEO of Institut Pasteur Korea, stated that IPK will utilize GEMCRO’s specialized GEM platform to enhance the precision of preclinical validation for vaccine and therapeutic candidates, adding that this partnership will serve as a catalyst for advancing new drug development for infectious diseases.
Han-Woong Lee, CEO of GEMCRO, emphasized that the collaboration represents a meaningful synergy between GEMCRO’s expertise in GEM-based disease model development and IPK’s specialized capabilities in infectious disease research. He expressed confidence that the partnership will lead the way in global infectious disease research and therapeutic innovation.